Detail akcie Hikma Pharma online

Business Summary: Hikma Pharmaceuticals PLC is a multinational pharmaceutical company engaged in the development, manufacturing and marketing of a broad range of generic, branded and specialty pharmaceutical products. Its pharmaceutical operations are conducted through three business segments: Injectables, Branded and Hikma Rx. It supplies hospitals across North America, Europe and the Middle East and North Africa (MENA) region with generic injectable and specialty medicines, supported by its growing global manufacturing network. It supplies branded generic and in-licensed products from its local manufacturing facilities to retail and hospital customers across the MENA region. Through Hikma Rx, it supplies oral, respiratory and other generic and specialty products to the North American market. Its manufacturing facilities in the United States (US) supply products across a broad range of therapeutic areas, including respiratory, oncology and pain management, serving customers in both the US and Canada.
Financial Summary: BRIEF: For the six months ended 30 June 2026, Hikma Pharmaceuticals Plc revenues increased 4% to $1.73B. Net income decreased 6% to $223M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net income was offset by Fair Value Adjustments on Other Assets decrease from $71M (income) to $0K, Research and development expenses increase of 18% to $86M (expense).